Stocks News

LAST PRICE
134.3100
TODAY'S CHANGE (%)
Trending Down-1.5200 (-1.1190%)

Bid / Lots
131.0000/ 3
Ask / Lots
139.8700/ 1
Open / Previous Close
136.1700 / 135.8300
Day Range
Low 134.0300
High 136.5500
52 Week Range
Low 93.0200
High 148.3699
Volume
889,349
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Jun 12, 2024
- DJ Neurocrine Is Maintained at Overweight by Morgan Stanley, from 1:14PM ET on Wednesday Jun 12, 2024 by Dow Jones
  1:14PM ET on Wednesday Jun 12, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/NBIX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  June 12, 2024 13:14 ET (17:14 GMT)
Jun 3, 2024
- Neurocrine Biosciences Presented CAHtalyst(TM) Phase 3 Pediatric and Adult Studies, CAHtalog(TM) Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024, from 8:01AM ET on Monday Jun 03, 2024 by Dow Jones
  8:01AM ET on Monday Jun 03, 2024 by Dow Jones
  Companies Mentioned: NBIX
  -- Acne--10% versus 6%
  "These data show a statistically higher clinical burden of CAH compared with a matched control, with patients of all ages suffering comorbidities that result from high adrenal androgens, such as short stature and hirsutism, and from supraphysiologic GC dosing, such as cardiovascular disease, metabolic disorders, and bone loss," Dr. Roberts said. "The data show that many of these comorbidities are chronic, with cardiovascular disease and the associated risk factors such as obesity and hypertension increasing in prevalence as patients age. This amplifies the clinical burden and demonstrates the significant need for a new treatment approach."
- Neurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine, from 7:35AM ET on Monday Jun 03, 2024 by Dow Jones
  7:35AM ET on Monday Jun 03, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  The CAHtalyst(TM) Pediatric and Adult Phase 3 global registrational studies are designed to evaluate the safety, efficacy, and tolerability of crinecerfont in children and adolescents, and adults respectively, with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. The primary portions of the CAHtalyst Phase 3 studies have completed and enrollment is closed, while the open-label extension treatment portions of both studies are ongoing. Data from the CAHtalyst Pediatric and CAHtalyst Adult Phase 3 studies supported two New Drug Application submissions to the U.S. Food and Drug Administration in April 2024.
- Neurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine, from 7:30AM ET on Monday Jun 03, 2024 by Dow Jones
  7:30AM ET on Monday Jun 03, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Crinecerfont is an investigational, oral, selective corticotropin-releasing factor type 1 receptor (CRF(1) ) antagonist being developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a glucocorticoid-independent mechanism for the treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. Antagonism of CRF(1) receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. Our data demonstrate that lowering adrenal androgen levels enables lower, more physiologic dosing of glucocorticoids and thus could potentially reduce the complications associated with exposure to greater than normal glucocorticoid doses in patients with CAH.
May 31, 2024
- Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing, from 3:49AM ET on Friday May 31, 2024 by MT Newswires
  3:49AM ET on Friday May 31, 2024 by MT Newswires
  Companies Mentioned: NBIX
  03:49 AM EDT, 05/31/2024 (MT Newswires) -- Stephen A Sherwin, Director, on May 29, 2024, sold 40,000 shares in Neurocrine Biosciences (NBIX) for $5,338,565. Following the Form 4 filing with the SEC, Sherwin has control over a total of 26,504 shares ...

Today
- United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors, from 15 hours ago by Business Wire
  15 hours ago by Business Wire
  Companies Mentioned: UTHR
- Wolfe Research Upgrades Qiagen to Outperform From Peer Perform, Price Target is $50, from 16 hours ago by MT Newswires
  16 hours ago by MT Newswires
  Companies Mentioned: QGEN
Yesterday
- Medpace Holdings, Inc. to Report Second Quarter 2024 Financial Results on July 22, 2024, from 4:05PM ET on Wednesday Jun 26, 2024 by Business Wire
  4:05PM ET on Wednesday Jun 26, 2024 by Business Wire
  Companies Mentioned: MEDP
- Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172, from 7:15AM ET on Wednesday Jun 26, 2024 by MT Newswires
  7:15AM ET on Wednesday Jun 26, 2024 by MT Newswires
  Companies Mentioned: SRPT
- Citigroup Upgrades Sarepta Therapeutics to Neutral From Buy, Adjusts PT to $176 From $172, from 6:10AM ET on Wednesday Jun 26, 2024 by MT Newswires
  6:10AM ET on Wednesday Jun 26, 2024 by MT Newswires
  Companies Mentioned: SRPT
Jun 25, 2024
- Tempus, United Therapeutics Launch Collaboration to Use AI to Detect Risk of Pulmonary Hypertension, from 10:22AM ET on Tuesday Jun 25, 2024 by MT Newswires
  10:22AM ET on Tuesday Jun 25, 2024 by MT Newswires
  Companies Mentioned: UTHR, TEM
Jun 24, 2024
- Morgan Stanley Adjusts Sarepta Therapeutics' Price Target to $200 From $165, Keeps Overweight Rating, from 12:40PM ET on Monday Jun 24, 2024 by MT Newswires
  12:40PM ET on Monday Jun 24, 2024 by MT Newswires
  Companies Mentioned: SRPT
- Evercore ISI Raises Price Target on Sarepta Therapeutics to $185 From $139, Maintains In Line Rating, from 11:30AM ET on Monday Jun 24, 2024 by MT Newswires
  11:30AM ET on Monday Jun 24, 2024 by MT Newswires
  Companies Mentioned: SRPT
- BMO Capital Raises Price Target on Sarepta Therapeutics to $200 From $170, Maintains Outperform Rating, from 8:08AM ET on Monday Jun 24, 2024 by MT Newswires
  8:08AM ET on Monday Jun 24, 2024 by MT Newswires
  Companies Mentioned: SRPT
Jun 21, 2024
- Sector Update: Health Care Stocks Gain in Late Afternoon, from 3:53PM ET on Friday Jun 21, 2024 by MT Newswires
  3:53PM ET on Friday Jun 21, 2024 by MT Newswires
  Companies Mentioned: LXRX, ITRM, SRPT, SHCR

Neurocrine Biosciences Inc
NASDAQ:NBIXUnited States

Search Criteria

Jun 12, 2024

DJ Neurocrine Is Maintained at Overweight by Morgan Stanley, from 1:14PM ET on Wednesday Jun 12, 2024 by Dow Jones

Jun 3, 2024

Neurocrine Biosciences Presented CAHtalyst(TM) Phase 3 Pediatric and Adult Studies, CAHtalog(TM) Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024, from 8:01AM ET on Monday Jun 03, 2024 by Dow Jones

Neurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine, from 7:35AM ET on Monday Jun 03, 2024 by Dow Jones

Neurocrine Biosciences Announces Publication of Primary CAHtalyst(TM) Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine, from 7:30AM ET on Monday Jun 03, 2024 by Dow Jones

May 31, 2024

Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing, from 3:49AM ET on Friday May 31, 2024 by MT Newswires

Peers Headlines

Today

United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors, from 15 hours ago by Business Wire

Wolfe Research Upgrades Qiagen to Outperform From Peer Perform, Price Target is $50, from 16 hours ago by MT Newswires

Yesterday

Medpace Holdings, Inc. to Report Second Quarter 2024 Financial Results on July 22, 2024, from 4:05PM ET on Wednesday Jun 26, 2024 by Business Wire

Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172, from 7:15AM ET on Wednesday Jun 26, 2024 by MT Newswires

Citigroup Upgrades Sarepta Therapeutics to Neutral From Buy, Adjusts PT to $176 From $172, from 6:10AM ET on Wednesday Jun 26, 2024 by MT Newswires

Jun 25, 2024

Tempus, United Therapeutics Launch Collaboration to Use AI to Detect Risk of Pulmonary Hypertension, from 10:22AM ET on Tuesday Jun 25, 2024 by MT Newswires

Jun 24, 2024

Morgan Stanley Adjusts Sarepta Therapeutics' Price Target to $200 From $165, Keeps Overweight Rating, from 12:40PM ET on Monday Jun 24, 2024 by MT Newswires

Evercore ISI Raises Price Target on Sarepta Therapeutics to $185 From $139, Maintains In Line Rating, from 11:30AM ET on Monday Jun 24, 2024 by MT Newswires

BMO Capital Raises Price Target on Sarepta Therapeutics to $200 From $170, Maintains Outperform Rating, from 8:08AM ET on Monday Jun 24, 2024 by MT Newswires

Jun 21, 2024

Sector Update: Health Care Stocks Gain in Late Afternoon, from 3:53PM ET on Friday Jun 21, 2024 by MT Newswires